Were Jennifer Baldock’s SGRY share sales discretionary or related to tax obligations?

The 10,082-share sale was related to tax obligations. A footnote states the shares were sold to satisfy her tax withholding requirements arising from the vesting of restricted stock that occurred on February 28, 2025 and March 2, 2025, rather than being a purely discretionary sale.

SGRY officer reports stock grants and tax sale

Surgery Partners, Inc. chief admin & development officer Jennifer Baldock reported multiple equity transactions in company common stock.

Filing Impact

(Very High)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Surgery Partners, Inc. chief admin & development officer Jennifer Baldock reported multiple equity transactions in company common stock. On March 5, 2026, she received several restricted stock awards totaling 106,307 shares at $14.11 per share, with tranches vesting over one to three years. On March 6, 2026, she sold 10,082 shares at $13.70 solely to cover tax withholding from recent vesting, and directly held 332,272 shares afterward.

Insider Trade Summary

Net Seller: 10,082 shares

Net Sell 4 txns

Insider Baldock Jennifer

Role Chief Admin & Dev Officer

Sold 10,082 shs ($138K)

Type	Security	Shares	Price	Value
Sale	Common Stock	10,082	$13.70	$138K
Grant/Award	Common Stock	42,523	$14.11	$600K
Grant/Award	Common Stock	40,909	$14.11	$577K
Grant/Award	Common Stock	22,875	$14.11	$323K

Holdings After Transaction: Common Stock — 332,272 shares (Direct)

Footnotes (4)

F1. Represents restricted stock awards ("RSAs") granted to the reporting person on March 5, 2026 (the "Grant Date"). The RSAs vest in three equal annual installments beginning on the first anniversary of the Grant Date.
F2. Represents restricted stock awards ("RSAs") granted to the reporting person on March 5, 2026 (the "Grant Date"). The RSAs vest on the first anniversary of the Grant Date.
F3. Represents restricted stock awards ("RSAs") granted to the reporting person on March 5, 2026 (the "Grant Date"). The RSAs vest on the second anniversary of the Grant Date.
F4. Shares sold to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock on February 28, 2025 and March 2, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did SGRY executive Jennifer Baldock report on this Form 4?

Jennifer Baldock reported receiving several restricted stock awards and selling shares to cover taxes. She acquired 106,307 restricted shares on March 5, 2026, then sold 10,082 shares on March 6, 2026, in an open-market transaction for tax withholding related to earlier vesting.

How many Surgery Partners (SGRY) shares did Jennifer Baldock sell, and at what price?

She sold 10,082 shares of Surgery Partners common stock at an average price of $13.70 per share. According to the footnote, these shares were sold specifically to satisfy tax withholding obligations tied to the vesting of restricted stock on February 28, 2025 and March 2, 2025.

What restricted stock awards did SGRY grant to Jennifer Baldock on March 5, 2026?

On March 5, 2026, she received restricted stock awards totaling 106,307 shares at $14.11 per share. One 22,875-share grant vests in three equal annual installments, while two other grants of 42,523 and 40,909 shares each vest on the first and second anniversaries of the grant date, respectively.

How many Surgery Partners shares does Jennifer Baldock own after these transactions?

Following the March 6, 2026 tax-related sale, Jennifer Baldock directly owned 332,272 shares of Surgery Partners common stock. Earlier totals disclosed in the filing reflect intermediate balances after each restricted stock award grant but before the final sale and updated post-transaction ownership figure.

What are the vesting terms of Jennifer Baldock’s new SGRY restricted stock awards?

The filing describes three vesting structures. One restricted stock award vests in three equal annual installments starting one year after March 5, 2026. Two additional restricted stock awards each vest fully on the first and second anniversaries of the March 5, 2026 grant date, respectively.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/09/2026 - 07:33 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Baldock Jennifer

(Last)

(First)

(Middle)

C/O SURGERY PARTNERS, INC.

340 SEVEN SPRINGS WAY, SUITE 600

(Street)

BRENTWOOD

37027

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Surgery Partners, Inc. [ SGRY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Admin & Dev Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/05/2026		A		42,523⁽¹⁾	A	$14.11	278,570	D
Common Stock	03/05/2026		A		40,909⁽²⁾	A	$14.11	319,479	D
Common Stock	03/05/2026		A		22,875⁽³⁾	A	$14.11	342,354	D
Common Stock	03/06/2026		S		10,082⁽⁴⁾	D	$13.7	332,272	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents restricted stock awards ("RSAs") granted to the reporting person on March 5, 2026 (the "Grant Date"). The RSAs vest in three equal annual installments beginning on the first anniversary of the Grant Date.

2. Represents restricted stock awards ("RSAs") granted to the reporting person on March 5, 2026 (the "Grant Date"). The RSAs vest on the first anniversary of the Grant Date.

3. Represents restricted stock awards ("RSAs") granted to the reporting person on March 5, 2026 (the "Grant Date"). The RSAs vest on the second anniversary of the Grant Date.

4. Shares sold to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock on February 28, 2025 and March 2, 2025.

Remarks:

	/s/ Jennifer Baldock	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR